Larry Johnston, DO
Gastroenterology · Ames, IANPI 1386036333
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,309 of the $5,370 with a category attached, or 61.6%. 29 manufacturers reported payments, led by Olympus Corporation Of The Americas at 29.4% of the total. Reporting peaked in 2022 at $1,953 and has fallen 77.6% since, to $437 in 2025.
Across 125 payments — averaging $42.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$2K
- AbbVie$1K
- QOL Medical, LLC$409
- Johnson & Johnson$389
- Janssen Scientific Affairs, LLC$302
- E.r. Squibb & Sons, L.L.C.$227
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$4007%
- Travel & lodging$1,49528%
- Food & beverage$3,30962%
- Education$1663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 11 | $1,581 |
| AbbVie | 38 | $1,004 |
| QOL Medical, LLC | 2 | $409 |
| Johnson & Johnson(2 entities) | 11 | $389 |
| Janssen Scientific Affairs, LLC | 3 | $302 |
| E.r. Squibb & Sons, L.L.C. | 2 | $227 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $212 |
| Phathom Pharmaceuticals, Inc. | 5 | $211 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $169 |
| Boston Scientific | 5 | $164 |
| Gilead | 3 | $132 |
| Medtronic | 1 | $117 |
| GSK | 4 | $80 |
| Intercept Pharmaceuticals, Inc. | 3 | $53 |
| Ironwood Pharmaceuticals, Inc | 3 | $43 |
| Pfizer | 2 | $32 |
| Novo Nordisk | 1 | $28 |
| Merck | 2 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Ardelyx, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Dova Pharmaceuticals | 1 | $18 |
| Bristol Myers Squibb | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $13 |
| Micro-tech Endoscopy USA, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VISIGLIDE$1,317
- Single Use Electrosurgical Knife KD-655$1,317
- DISPOSABLE DISTAL ATTACHMENT$1,317
- Olympus$1,317
- Single Use Aspiration Needle NA-U200H$618
- Sucraid$400
- Skyrizi$235
- ZEPOSIA$227
- STELARA$124
- Barrx$117
- Mavyret$112
How this compares
$5,370 in reported general payments places this provider in the 85th percentile of 113 gastroenterology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 222 | $14,423 |
| LinzessLinaclotide | 14 | $10,407 |
| Budesonide DrBudesonide | 11 | $3,954 |
| Mesalamine DrMesalamine | 11 | $3,505 |
| Omeprazole | 183 | $1,726 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 51 | $660 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 26 | $350 |
| Esomeprazole Magnesium | 14 | $339 |
| Nortriptyline Hcl | 18 | $285 |
| Sulfasalazine | 17 | $213 |
| Famotidine | 17 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,004 | $10,40714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 113 gastroenterology providers in Iowa.
Other gastroenterology in Ames
- Nagendra MyneniClive$66K
- Ryan PerumpailBettendorf$62K
- Richard ManfreadyWaterloo$56K
- Maen MasadehIowa City$24K
- Mohammed IrshadClinton$18K
- John HerlihyCedar Rapids$13K
- Bernard LemanClive$12K
- Archana VermaClive$6K
- Daniel PeasleyWest Burlington$6K
- Christopher MulderClive$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.